[go: up one dir, main page]

AU2001255196A1 - Compositions and methods for enhancing immunogenicity of antigens - Google Patents

Compositions and methods for enhancing immunogenicity of antigens

Info

Publication number
AU2001255196A1
AU2001255196A1 AU2001255196A AU5519601A AU2001255196A1 AU 2001255196 A1 AU2001255196 A1 AU 2001255196A1 AU 2001255196 A AU2001255196 A AU 2001255196A AU 5519601 A AU5519601 A AU 5519601A AU 2001255196 A1 AU2001255196 A1 AU 2001255196A1
Authority
AU
Australia
Prior art keywords
antigens
compositions
methods
enhancing immunogenicity
immunogenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255196A
Inventor
George Raymond Gunn Iii
Yvonne Paterson
Christian Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/537,642 external-priority patent/US6855320B2/en
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2001255196A1 publication Critical patent/AU2001255196A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001255196A 2000-03-29 2001-03-26 Compositions and methods for enhancing immunogenicity of antigens Abandoned AU2001255196A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09537642 2000-03-29
US09/537,642 US6855320B2 (en) 2000-03-29 2000-03-29 Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US09735450 2000-12-13
US09/735,450 US6767542B2 (en) 2000-03-29 2000-12-13 Compositions and methods for enhancing immunogenicity of antigens
PCT/US2001/009736 WO2001072329A1 (en) 2000-03-29 2001-03-26 Compositions and methods for enhancing immunogenicity of antigens

Publications (1)

Publication Number Publication Date
AU2001255196A1 true AU2001255196A1 (en) 2001-10-08

Family

ID=27065568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255196A Abandoned AU2001255196A1 (en) 2000-03-29 2001-03-26 Compositions and methods for enhancing immunogenicity of antigens

Country Status (7)

Country Link
US (3) US7635479B2 (en)
EP (1) EP1303299B1 (en)
JP (1) JP2004500405A (en)
AU (1) AU2001255196A1 (en)
CA (1) CA2404164A1 (en)
IL (1) IL151942A0 (en)
WO (1) WO2001072329A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
KR101192652B1 (en) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060135457A1 (en) * 2004-08-13 2006-06-22 Yvonne Paterson Methods for constructing antibiotic resistance free vaccines
PT2942391T (en) 2004-08-13 2018-10-09 Univ Pennsylvania Methods for constructing antibiotic resistance free vaccines
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
SI1991263T1 (en) * 2006-03-01 2015-03-31 Aduro Biotech Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
EP2056849A4 (en) * 2006-08-04 2010-09-08 Univ Pennsylvania METHODS AND COMPOSITIONS FOR TREATING IGE MEDIATED DISEASES
US8241636B2 (en) 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
AU2008323848B2 (en) 2007-11-07 2014-09-25 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US8573465B2 (en) 2008-02-14 2013-11-05 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical end effector system with rotary actuated closure systems
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010102140A1 (en) 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
RU2015132478A (en) 2009-03-05 2015-12-10 Эббви Инк. BINDING IL-17 PROTEINS
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSATE VACCINE INSENSITIVITY IN INDIVIDUALS INFECTED BY PARASITES
WO2012112317A1 (en) 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
US10058599B2 (en) 2012-03-12 2018-08-28 Advaxis, Inc. Suppressor cell function inhibition following Listeria vaccine treatment
WO2014106123A1 (en) * 2012-12-27 2014-07-03 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
CA2946716A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
SG10201913696YA (en) 2014-07-18 2020-03-30 Advaxis Inc Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10010593B2 (en) 2014-10-14 2018-07-03 The Trustees Of The University Of Pennsylvania Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
CN107278206B (en) 2014-12-19 2021-04-02 雷根尼桑斯公司 Antibodies that bind to human C6 and uses thereof
MA41217A (en) * 2014-12-19 2017-10-24 Advaxis Inc POLYTHERAPIES WITH RECOMBINATED LISTERIA STRAINS
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
MA44379A (en) 2015-04-13 2019-01-23 Aduro Biotech Inc EPIDERMAL-MESOTHELIN GROWTH FACTOR RECEPTOR VARIANT III FUSIONS AND METHODS OF USE
CN107980044A (en) 2015-04-13 2018-05-01 艾杜罗生物科技公司 Immunogenic fusion proteins for treating cancer
US10350748B2 (en) * 2016-02-12 2019-07-16 Matco Tools Corporation Tool storage unit having a moveable housing
KR102414558B1 (en) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. Agonistic antibodies that bind to human CD40 and uses thereof
WO2018085854A1 (en) * 2016-11-07 2018-05-11 Advaxis, Inc. Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies
CN110506107A (en) 2016-11-30 2019-11-26 阿德瓦希斯公司 Immunogenic compositions targeting recurrent cancer mutations and methods of use
EP4527412A3 (en) 2017-09-19 2025-06-11 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
JP2021516972A (en) 2018-03-09 2021-07-15 アドバクシス， インコーポレイテッド Compositions and Methods for Assessing Attenuation and Infectivity of Listeria Strains
JP7466459B2 (en) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド Anti-CD27 and Anti-PD-L1 Antibodies and Bispecific Constructs
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CN111979162B (en) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 Recombinant BCG vaccine strain, its preparation method and use
MX2023000105A (en) 2020-06-23 2023-04-25 Univ Colorado Regents Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes.
US20240091380A1 (en) 2021-02-01 2024-03-21 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CN117545773A (en) 2021-04-09 2024-02-09 塞德斯医疗公司 anti-ILT 4 antibodies, bispecific anti-ILT 4/PD-L1 antibodies and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567041A (en) 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4816253A (en) 1977-12-08 1989-03-28 Likhite Vilas V Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
CA1156952A (en) 1979-06-08 1983-11-15 Zacharia M. George Formation of coke from heavy crude oils in the presence of calcium carbonate
US5262177A (en) 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
JPS63173594A (en) 1986-08-29 1988-07-18 Medeisa Shinyaku Kk Secretory protein induced by carcinogenic gene
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
JPH0832888B2 (en) 1988-01-07 1996-03-29 田島ルーフィング株式会社 Asphalt melting pot for waterproof construction
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
CA2055441C (en) 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
FR2686896B1 (en) 1992-01-31 1995-01-06 Pasteur Institut MUTANT ATTENUE OF LISTERIA MONOCYTOGENES; RECOMBINANT STRAIN OF LISTERIA MONOCYTOGENES, USE AS HETEROLOGOUS VECTORS OF VACCINE ANTIGENS AND USE AS VACCINE OR DIAGNOSTIC COMPOSITION.
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
CA2109176C (en) 1993-10-25 1998-06-16 Roman Koszarycz Prevention of sulfur gas emissions from a rotary processor using lime addition
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
JPH08278554A (en) * 1995-04-06 1996-10-22 Nikon Corp Device capable of loading film cartridge
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
DE19541450C2 (en) 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Gene construct and its use
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5788329A (en) * 1996-02-08 1998-08-04 Pilarczyk; Ervin Robert Fold-down seat for a motor vehicle
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US5681670A (en) * 1996-07-26 1997-10-28 Mitsubishi Chemical Corporation Electrode support in a multilayer cell
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
DE69734605T2 (en) 1997-04-18 2006-08-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Weakened salmonella, used as a vechicle for oral immunization
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP0934421A1 (en) 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. DNA INTEGRATION INTO "MYCOBACTERIUM spp." GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6355320B1 (en) * 1998-10-21 2002-03-12 Nomacorc, Llc Synthetic closure and manufacturing process thereof
US6818002B2 (en) 1999-02-02 2004-11-16 Samuel Shiber Vessel cleaner and barrier
DE19949594A1 (en) 1999-10-14 2001-04-26 Deutsches Krebsforsch Recombinant attenuated listeria for immunotherapy
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
TW512968U (en) * 2000-12-12 2002-12-01 Delta Electronics Inc Winding tube of transformer
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1497654A4 (en) 2001-08-13 2006-06-07 Chen Swey Shen Alex Immunoglobulin e vaccines and methods of use thereof
CA2474728A1 (en) 2002-02-06 2003-08-14 Johns Hopkins University School Of Medicine Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US8337861B2 (en) 2003-01-09 2012-12-25 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
KR101192652B1 (en) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
PT2942391T (en) 2004-08-13 2018-10-09 Univ Pennsylvania Methods for constructing antibiotic resistance free vaccines
JP2008516614A (en) 2004-10-18 2008-05-22 メディミューン，インコーポレーテッド High cell density method for Listeria growth
US7495006B2 (en) * 2004-12-10 2009-02-24 Emory University 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines

Also Published As

Publication number Publication date
EP1303299B1 (en) 2010-07-28
IL151942A0 (en) 2003-04-10
US20050118184A1 (en) 2005-06-02
US7635479B2 (en) 2009-12-22
EP1303299A1 (en) 2003-04-23
US20070003567A1 (en) 2007-01-04
US7588930B2 (en) 2009-09-15
CA2404164A1 (en) 2001-10-04
US20060204516A1 (en) 2006-09-14
EP1303299A4 (en) 2005-01-26
WO2001072329A1 (en) 2001-10-04
US7655238B2 (en) 2010-02-02
JP2004500405A (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
AU2903999A (en) Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
AU2002224079A1 (en) O/W emulsion composition and method of preparing the same
HUP0301394A3 (en) Methods and composition for oral vaccination
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
AU2000265991A1 (en) Novel method of preparing p-phenylenediamine
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2001295672A1 (en) Vaccine composition and stabilisation method
AU2001236525A1 (en) Neutralizing antibody and immunomodulatory enhancing compositions
AU2952202A (en) Immunogenic compositions comprising liver stage malarial antigens
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2001251352A1 (en) Brake cleaner compositions and method of using same
AU2001253481A1 (en) Methods and compositions for eleciting an immune response
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2001271801A1 (en) Compositions and methods for producing recombinant virions
AU2001267541A1 (en) Vaccine composition
AU2001276581A1 (en) Compositions for inducing self-specific anti-ige antibodies and uses thereof
AU3364000A (en) Antigen of erysipelothirx rhusiopathiae comprising an immuno-protective epitope
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases